On Sept. 28, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program) that demonstrated durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern.

The article, titled “Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1,” was posted as an accelerated preprint on bioRxiv.